F-box protein 9Genealiases: FBX9 · NY-REN-57 · VCIA1 · dJ341E18.2
Q-omics provides the consensus-scored FBXO9 profile across patient tissues and cancer cell-line models. FBXO9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, FBXO9 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, FBXO9 RNA expression shows 20,052 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, LUAD, and ACC as cancer lineages where FBXO9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO9 survival associations across molecular data types. FBXO9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO9 RNA expression–survival associations across cancer types. High FBXO9 expression shows unfavorable associations in ACC and KIRP, but favorable associations in PAAD, KIRC, MESO and OV. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for FBXO9 RNA expression.
This table summarizes FBXO9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO9 shows lower tumor expression in LUAD, KICH, THCA, KIRP and KIRC and higher tumor expression in LIHC. The LUAD box plot shows higher FBXO9 RNA expression in normal versus tumor tissue (log2 FC = −0.704, t-test p < 0.001).
This table shows molecular features associated with FBXO9 in patient tissues and cancer cell lines. In patient samples, FBXO9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
